Radotinib, also known by its investigational code IY5511, is an oral Bcr-Abl tyrosine-kinase inhibitor used in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It was developed by Il-Yang Pharmaceutical Co., Ltd and is marketed as an oral small-molecule therapy that selectively inhibits Bcr-Abl kinase activity, reducing downstream signaling through STAT, MAPK and PI3K-Akt pathways; radotinib displays potency against wild-type Bcr-Abl and several clinically relevant Abl point mutants while showing limited activity against the T315I substitution. The active pharmaceutical ingredient is characterized by high in vitro binding affinity for the Abl ATP-binding site, is predominantly metabolized by cytochrome P450 3A isoforms, and requires monitoring for drug interactions with strong CYP3A inhibitors or inducers. Formulation and stability data indicate suitability for film-coated oral dosage forms with standard storage controls to limit oxidation and hydrolytic degradation.
Typical quality specifications for radotinib active substance and finished product control a defined set of related compounds and degradation products; identified related compounds commonly monitored include N-desmethyl-radotinib, radotinib N-oxide, oxidative ring-opened species and minor dehalogenated analogues. Representative specification limits used in regulatory filings and quality control are: individual identified impurities controlled to not exceed 0.10 percent weight by weight, individual unspecified impurities limited to 0.05 percent w/w, and total impurities (sum of specified and unspecified) limited to not exceed 0.50 percent w/w. Analytical control strategies use validated HPLC with orthogonal MS or PDA confirmation and forced-degradation studies to establish these limits for batch release and stability testing.
Radotinib binds the ATP-binding pocket of the Bcr-Abl tyrosine kinase, stabilizing the kinase in an inactive conformation and preventing phosphorylation of downstream effectors; this leads to inhibition of proliferative and survival signaling in Bcr-Abl positive leukemic cells. The compound inhibits wild-type Bcr-Abl and many single-point mutants, but activity is limited against the gatekeeper T315I mutation. In cellular models this results in apoptosis and reduced colony formation of Philadelphia chromosome-positive cells.
Radotinib has been developed for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia and has been evaluated in clinical trials as a second-line and later-line oral therapy in patients resistant or intolerant to prior Bcr-Abl inhibitors. Local regulatory approvals and marketed indications vary by country and are dependent on national regulatory decisions and labeling.
Safety monitoring focuses on hematologic parameters, hepatic function and cardiac monitoring for QT interval prolongation in susceptible patients. Because radotinib is primarily metabolized by CYP3A enzymes, coadministration with strong CYP3A inhibitors may increase exposure and require dose adjustment or avoidance, while strong CYP3A inducers may reduce exposure. Concomitant use of other drugs that prolong the QT interval should be approached with caution.
Impurities and related compounds are quantified using validated stability-indicating HPLC methods with UV detection and mass spectrometric confirmation for identity. Method validation covers specificity, sensitivity, accuracy, precision and linearity; limits of detection and quantification are set to meet the impurity thresholds described in the product specification. Forced-degradation studies under oxidative, photolytic, acidic, basic and thermal conditions are used to establish degradation pathways and identify potential impurities.
